-
公开(公告)号：US09850242B2
公开(公告)日：2017-12-26
申请号：US15233520
申请日：2016-08-10
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Roch Boivin , Eric Carlson , Atsushi Endo , Hans Hansen , Lynn D. Hawkins , Sally Ishizaka , Matthew Mackey , Sridhar Narayan , Takashi Satoh , Shawn Schiller
IPC: A01N43/90 , A61K31/519 , C07D471/04 , C07D487/04 , A61K31/55
CPC classification number: C07D471/04 , A61K31/519 , A61K31/55 , C07D487/04 , Y02P20/582
Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
-
公开(公告)号：US20160339032A1
公开(公告)日：2016-11-24
申请号：US15233520
申请日：2016-08-10
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Roch Boivin , Eric Carlson , Atsushi Endo , Hans Hansen , Lynn D. Hawkins , Sally Ishizaka , Matthew Mackey , Sridhar Narayan , Takashi Satoh , Shawn Schiller
IPC: A61K31/519 , A61K31/55
CPC classification number: C07D471/04 , A61K31/519 , A61K31/55 , C07D487/04 , Y02P20/582
Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis
-
公开(公告)号：US09446046B2
公开(公告)日：2016-09-20
申请号：US14806174
申请日：2015-07-22
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Roch Boivin , Eric Carlson , Atsushi Endo , Hans Hansen , Lynn D. Hawkins , Sally Ishizaka , Matthew Mackey , Sridhar Narayan , Takashi Satoh , Shawn Schiller
IPC: A01N43/90 , A61K31/519 , C07D471/04 , C07D487/04
CPC classification number: C07D471/04 , A61K31/519 , A61K31/55 , C07D487/04 , Y02P20/582
Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
-
公开(公告)号：US09382262B2
公开(公告)日：2016-07-05
申请号：US14577417
申请日：2014-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Atsushi Endo , Charles E. Chase , Francis G. Fang
IPC: C07D407/06 , C07D493/04 , C07D405/06 , C07D405/12 , C07D307/38
CPC classification number: C07F7/1804 , C07D307/12 , C07D307/38 , C07D405/06 , C07D405/12 , C07D407/06 , C07D493/04 , Y02P20/55
Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate. Exemplary compounds are of formula (I), (II), or (III):
-
公开(公告)号：US12251394B2
公开(公告)日：2025-03-18
申请号：US17058817
申请日：2019-05-31
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Dae-Shik Kim , Frank Fang , Atsushi Endo , Hyeong-Wook Choi , Ming-Hong Hao , Xingfeng Bao , Kuan-Chun Huang
IPC: A61K31/7084 , A61P35/04
Abstract: Provided herein are methods for the treatment of bladder cancer.
-
Patent Agency Ranking
16.发明授权公开(公告)号：US10981929B2
公开(公告)日：2021-04-20
申请号：US16313196
申请日：2017-06-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Charles E. Chase , Hyeong-Wook Choi , Atsushi Endo , Francis G. Fang , Dae-Shik Kim
IPC: C07D493/22
Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
-
公开(公告)号：US10457698B2
公开(公告)日：2019-10-29
申请号：US15750087
申请日：2016-08-05
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Atsushi Endo , Robert T. Yu , Francis Fang , Hyeong Wook Choi , Mingde Shan
IPC: C07D413/00 , C07F9/6561 , C07F9/6558 , C07H21/00 , A61K31/7088
Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided:
-
公开(公告)号：US10214539B2
公开(公告)日：2019-02-26
申请号：US15787268
申请日：2017-10-18
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Charles E. Chase , Atsushi Endo , Francis G. Fang , Jing Li
IPC: C07D493/20 , C07D307/28 , C07D307/33 , C07D493/08 , C07D493/18 , C07D493/04 , C07D493/22 , C07D307/20 , C07D307/26 , C07D309/16 , C07D405/06 , C07D405/14
Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
-
公开(公告)号：US20180222932A1
公开(公告)日：2018-08-09
申请号：US15750087
申请日：2016-08-05
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Atsushi Endo , Robert T. Yu , Francis Fang , Hyeong Wook Choi , Mingde Shan
IPC: C07F9/6561 , C07F9/6558
Abstract: We provide diastereomerically pure or substantially diastereomerically pure activated phosphoramidochloridate morpholino nucleosides, methods of their preparation, and methods of their use in stereospecific coupling for stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs).
-
公开(公告)号：US09604993B2
公开(公告)日：2017-03-28
申请号：US14624033
申请日：2015-02-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Charles E. Chase , Atsushi Endo , Francis G. Fang , Jing Li
IPC: C07D493/20 , A61K31/335 , C07D307/28 , C07D307/33 , C07D493/08 , C07D493/18
CPC classification number: C07D493/20 , C07D307/20 , C07D307/26 , C07D307/28 , C07D307/33 , C07D309/16 , C07D405/06 , C07D405/14 , C07D493/04 , C07D493/08 , C07D493/18 , C07D493/22 , Y02P20/55
Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.019 seconds)
